PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
XEN-D0501, the recently purchased, safe clinical development candidate, will enter the first clinical trials in type-2 diabetic patients in 2017.
Dr. Dorte X. Gram has accepted to give a talk entitled: ‘If I’m right, this could be a really big thing! – daring to challenge status-quo in diabetes treatment’
Prague Summer School – Advances in Drug Discovery
September 4-8, 2017
Prague, Czech Republic